Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sanjie Tongluo decoction is a Traditional Chinese Medicine (TCM) formulation developed by Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. It is specifically designed to treat pulmonary pure ground-glass nodules (pGGNs) in patients diagnosed with the 'qi deficiency and phlegm stasis' TCM pattern. The treatment is typically administered in granule form. Clinical evaluation focuses on its efficacy in reducing nodule diameter, volume, and density, as well as improving TCM-specific symptoms, psychological well-being, and overall quality of life. The decoction's therapeutic approach is based on TCM principles of tonifying qi, resolving phlegm, and dispersing blood stasis to counteract the pathological formation of lung nodules.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sanjie Tongluo decoction.